LANXESS AG/€LXS
1D1W1MYTD1Y5YMAX
Capital at risk
About LANXESS AG
LANXESS AG is a specialty chemicals company headquartered in Cologne, Germany. It operates in the chemical industry, focusing on the production of chemical intermediates, additives, specialty chemicals, and plastics. The company's product segments cater to various sectors, including construction, automotive, agriculture, and consumer goods. Established in 2004, LANXESS was formed through a spinoff from Bayer AG. Its global presence spans over 30 countries, with significant operations in Europe, North America, and Asia. The company emphasizes sustainable practices and innovation in its product development to maintain competitive strengths within its industry.
- Ticker
- €LXS
- Sector
- Materials
- Primary listing
- XETRA
- Employees
- 11,495
- Headquarters
- Cologne, Germany
- Website
- lanxess.com
LANXESS AG Metrics
BasicAdvanced
€1.2B
-
-€7.75
1.15
€0.10
0.73%
Price and volume
Market cap
€1.2B
Beta
1.15
52-week high
€24.76
52-week low
€11.04
Average daily volume
481K
Dividend rate
€0.10
Financial strength
Current ratio
1.803
Quick ratio
0.896
Long term debt to equity
0.66
Total debt to equity
0.855
Interest coverage (TTM)
-3.47%
Profitability
EBITDA (TTM)
293
Gross margin (TTM)
19.37%
Net profit margin (TTM)
-12.06%
Operating margin (TTM)
-2.69%
Effective tax rate (TTM)
-24.21%
Revenue per employee (TTM)
€480,000
Management effectiveness
Return on assets (TTM)
-1.11%
Return on equity (TTM)
-17.83%
Valuation
Price to revenue (TTM)
0.213
Price to book
0.34
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
15.307
Free cash flow yield (TTM)
6.53%
Free cash flow per share (TTM)
0.892
Dividend yield (TTM)
0.73%
Forward dividend yield
0.73%
Growth
Revenue change (TTM)
-9.81%
Earnings per share change (TTM)
305.45%
3-year revenue growth (CAGR)
-10.88%
10-year revenue growth (CAGR)
-3.13%
3-year earnings per share growth (CAGR)
-18.22%
10-year earnings per share growth (CAGR)
14.44%
3-year dividend per share growth (CAGR)
-54.33%
10-year dividend per share growth (CAGR)
-16.40%
Bulls say / Bears say
Geopolitical supply disruptions among Asian competitors due to the Middle East conflict have provided temporary tailwinds to LANXESS, enabling consecutive increases in sales volumes since March and reduced Asian price pressure. (Reuters) (marketscreener.com)
The group has enacted ambitious cost-reduction measures— including the elimination of 550 positions and plans to achieve an additional €100 million of annual savings by 2028—aimed at strengthening its balance sheet and restoring investment-grade credit status. (Reuters) (marketscreener.com)
Management reaffirmed its full-year 2026 EBITDA pre exceptionals guidance of €450–550 million, signaling confidence in navigating ongoing market uncertainties. (Reuters) (marketscreener.com)
Speciality chemicals maker LANXESS reported annual 2025 sales below market expectations and warned that business is unlikely to improve before the second half of 2026, reflecting persistent demand weakness across its end-markets. (Reuters) (uk.finance.yahoo.com)
Credit rating agency Moody’s recently downgraded LANXESS to junk status, heightening concerns over leverage and increasing its cost of capital. (Reuters) (marketscreener.com)
Germany’s chemical lobby VCI forecasts a 1.5% decline in industry output for 2026 due to weak European demand and investment shifts, underscoring challenging operating conditions for LANXESS in its core markets. (Reuters) (stockopedia.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Upcoming events
No upcoming events
Funds containing LANXESS AG
AllEURGBPUSD
Fund name | Fund size | €LXS weighting |
|---|---|---|
iShares MDAX€EXID | €34M | 0.67% |
iShares MDAX€EXS3 | €1.5B | 0.67% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.24% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.09% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.